Trial Outcomes & Findings for FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders (NCT NCT01028820)
NCT ID: NCT01028820
Last Updated: 2014-03-11
Results Overview
The Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version (CY-BOCS-PDD) is a clinician-rated interview designed to evaluate repetitive behavior in children with pervasive developmental disorders (PDDs). It is a modification of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), developed to assess typically-developing children with obsessive compulsive behavior. Because of language limitations in children with PDDs the CY-BOCS-PDD only includes the five compulsion items: Time Spent, Interference, Distress, Resistance of repetitive behavior, and Control of repetitive behavior. Each item is rated from 0 (none) through 4 (extreme), and scores can range from 0 to 20, with higher scores reflecting more severe symptoms. Usually a score \> than 8 is considered clinically significant.
COMPLETED
PHASE4
13 participants
Baseline ("Pre-Dose") to 8 Weeks ("Post-Dose")
2014-03-11
Participant Flow
We planned to recruit participants through the NDRC Registry and Division TEACCH, as well as utilizing radio and television ads on various stations. We also posted brochures and flyers in public locations and attended conferences in order to hand out study-specific information. 13 subjects began the study and only one of those failed to complete.
In order to participate in the research study, subjects must have been washed out from psychoactive medication for at least one month for fluoxetine, two weeks for other SSRIs and neuroleptics and five days for stimulants prior to MRI scanning, with the exception of stable doses greater than three months duration of medication for seizure disorder.
Participant milestones
| Measure |
Open-Label, Flexible-Dose Aripiprazole
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Aripiprazole : 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
|
|---|---|
|
Overall Study
STARTED
|
13
|
|
Overall Study
COMPLETED
|
12
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
Baseline characteristics by cohort
| Measure |
Open-Label, Flexible-Dose Aripiprazole
n=13 Participants
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Aripiprazole : 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
|
|---|---|
|
Age, Continuous
|
20.31 years
STANDARD_DEVIATION 5.1 • n=99 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
12 Participants
n=99 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=99 Participants
|
|
Race (NIH/OMB)
White
|
9 Participants
n=99 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Baseline ("Pre-Dose") to 8 Weeks ("Post-Dose")Population: All randomized participants' scores were analyzed using the PDD-CYBOCS measure. Higher values reflect worse outcomes. Subscales are added to compute the total score (total score does not include compulsion free-interval and peculiarity of the behavior.
The Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version (CY-BOCS-PDD) is a clinician-rated interview designed to evaluate repetitive behavior in children with pervasive developmental disorders (PDDs). It is a modification of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), developed to assess typically-developing children with obsessive compulsive behavior. Because of language limitations in children with PDDs the CY-BOCS-PDD only includes the five compulsion items: Time Spent, Interference, Distress, Resistance of repetitive behavior, and Control of repetitive behavior. Each item is rated from 0 (none) through 4 (extreme), and scores can range from 0 to 20, with higher scores reflecting more severe symptoms. Usually a score \> than 8 is considered clinically significant.
Outcome measures
| Measure |
Open-Label, Flexible-Dose Aripiprazole: Baseline (Pre-Dose)
n=13 Participants
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Aripiprazole : 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
|
Open-Label, Flexible-Dose Aripiprazole: 8 Weeks (Post-Dose)
n=13 Participants
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Aripiprazole : 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
|
|---|---|---|
|
Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version
|
12.7 Scores on a scale
Standard Deviation 2.250
|
8.6 Scores on a scale
Standard Deviation 3.50
|
SECONDARY outcome
Timeframe: baseline week 0, 8 weeksPopulation: All randomized participants' scores were analyzed using the RBS-R measure. Higher values reflect worse outcomes (greater symptom severity). Subscales are added to compute the total score.
The RBS-R is an assessment that includes Sameness, Self-Injurious Behavior, Ritualistic, Compulsive, and Restrictive Behavior subscales. The assessments are completed by caregivers for the past week, with consideration of frequency,ease of redirecting and extent to which behavior interferes with functioning compared to a typically developing child of the same age and gender. Scores are rated from 0 - behavior does not occur to 3 - behavior occurs and is a serious problem. There are 43 items and 5 subscales. Higher scores indicate greater symptom severity. total score is the sum of all items in all subscales. The subscales are stereotyped behaviors 6 items, self-injurious behaviors 8 items, Compulsive behaviors- 8 items, Ritualistic Behaviors 6 items, Sameness 11 items, restricted behaviors 4 items.Total score ranges from 0 to 129.
Outcome measures
| Measure |
Open-Label, Flexible-Dose Aripiprazole: Baseline (Pre-Dose)
n=13 Participants
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Aripiprazole : 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
|
Open-Label, Flexible-Dose Aripiprazole: 8 Weeks (Post-Dose)
n=13 Participants
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Aripiprazole : 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
|
|---|---|---|
|
Total Repetitive Behavior Scale - Revised (RBS_R)
|
42.2 units on a scale
Standard Deviation 18.37
|
20.5 units on a scale
Standard Deviation 13.79
|
Adverse Events
Open-Label, Flexible-Dose Aripiprazole
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Open-Label, Flexible-Dose Aripiprazole
n=13 participants at risk
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Aripiprazole : 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
|
|---|---|
|
Social circumstances
Anxiety
|
15.4%
2/13 • Number of events 2
|
|
General disorders
Body Pain
|
23.1%
3/13 • Number of events 3
|
|
Psychiatric disorders
Depressed Mood
|
7.7%
1/13 • Number of events 1
|
|
General disorders
Drowsiness
|
7.7%
1/13 • Number of events 1
|
|
General disorders
Dry Mouth
|
7.7%
1/13 • Number of events 1
|
|
General disorders
Fatigue
|
53.8%
7/13 • Number of events 7
|
|
Metabolism and nutrition disorders
Increased Appetite
|
23.1%
3/13 • Number of events 3
|
|
General disorders
Increased Sleep
|
15.4%
2/13 • Number of events 2
|
|
General disorders
Nausea
|
7.7%
1/13 • Number of events 1
|
|
Blood and lymphatic system disorders
Neutropenia
|
7.7%
1/13 • Number of events 1
|
|
General disorders
Restlessness
|
23.1%
3/13 • Number of events 3
|
|
Ear and labyrinth disorders
Tinnitus
|
7.7%
1/13 • Number of events 1
|
|
Nervous system disorders
Tremors
|
7.7%
1/13 • Number of events 1
|
|
Renal and urinary disorders
Urination
|
7.7%
1/13 • Number of events 1
|
|
Metabolism and nutrition disorders
Weight Gain
|
23.1%
3/13 • Number of events 3
|
Additional Information
Linmarie Sikich, M.D.
The University of North Carolina at Chapel Hill
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place